Establish an important cooperation with the University of South Australia, a famous university in Australia, to jointly develop new cancer therapies

Yabao Pharmaceutical (Shanghai Securities: 600351) announced on September 6, 2015 that it had established an important cooperation with the University of South Australia, a famous university in Australia, to jointly develop new cancer therapies.
According to the terms of the agreement, the team led by Professor Wang Shudong of the University of South Australia is responsible for the development of candidate compounds in the joint venture laboratory.
Yabao pharmaceutical provides all material support for drug discovery and development, and obtains the right to develop and sell candidate drugs in China, while the University of South Australia will retain the right to all other markets. Dr. Wang Peng, President of research and development of Yabao pharmaceutical, said: "we are very pleased to have the opportunity to cooperate with influential scientists and laboratories of the University of South Australia to jointly develop a new method to treat cancer. Yabao continues to seek opportunities to establish cooperative relations with institutions with innovative projects to improve the company's development and business capabilities."
Professor David Lloyd, President and vice chancellor of the University of South Australia, said: "there are no international obstacles in research and development. Cancer has always been one of the major challenges facing the world. We are glad to establish such a strong cooperation in China, which will improve the development of new cancer therapies. We will work closely with Yabao pharmaceutical to develop new anti-cancer drugs." Professor Wang Shudong, head of the drug discovery and development center of the University of South Australia, said: "the agreed funds will help to quickly promote our drug discovery, accelerate the clinical process and finally achieve our common goal." she looks forward to fruitful cooperation with Yabao to provide a strong guarantee for the drug R & D project of the center.
About Yabao pharmaceutical
Yabao Pharmaceutical (Shanghai Securities 600351) is a Chinese pharmaceutical enterprise with perfect drug development, production and commercialization capacity in China. Recently, Yabao has adjusted its strategic development direction, aiming at the field of innovative drugs in addition to its mature cause in the field of modern Chinese traditional medicine and chemical generic drugs. Yabao has strong clinical and regulatory capabilities. The production of preparations and APIs meets the requirements of drug production quality management practices (CGMP) and has passed the inspection of FDA and EU drug regulatory authorities respectively.
About the University of South Australia
The University of South Australia focuses on the world on the principle of fairness and excellence. It is actively establishing close ties with universities in Asia, Europe, North America and other countries and regions, and making extensive exchanges in teaching, research, consulting and continuing education.
At present, the university has more than 35000 officially registered students and more than 2000 teaching staff. It is a young university in South Australia. In 2014, Thames World University of higher education ranked among the top 50 among the top 100 universities with less than 50 years of establishment.
The university has a strong education and research background in health science, with pharmacology and pharmacy. The health and Medical Research Institute of the University of South Australia received $2.3 million to establish a new health and biomedical research area in downtown Adelaide.

Next:It is authorized by primary peptides, Inc. in China to develop and sell innovative drugs targeting PTEN for the treatment of stroke